CEFOTAXIME SODIUM FOR INJECTION BP 2 G — DIN 02352184
CEFOTAXIME SODIUM : 2 G · AUROBINDO PHARMA LIMITED (UNIT VI) · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: APPROVED
What is CEFOTAXIME SODIUM FOR INJECTION BP?
CEFOTAXIME SODIUM FOR INJECTION BP 2 G contains CEFOTAXIME SODIUM : 2 G. It is listed in the Health Canada Drug Product Database under DIN 02352184, held by AUROBINDO PHARMA LIMITED (UNIT VI), supplied as POWDER FOR SOLUTION for INTRAMUSCULAR ; INTRAVENOUS administration. Health Canada currently lists it as approved, status dated 28-May-2010. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is CEFOTAXIME SODIUM FOR INJECTION BP used for?
Treatment of susceptible infections: lower respiratory tract, urinary tract, gonorrhea, bacteremia/septicemia, skin, intra-abdominal, gynecological, and CNS infections (meningitis). Surgical prophylaxis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Cefotaxime cost around the world?
Cefotaxime is listed on 6 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory); Morocco publishes a PPV (public price). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| South Africa | single exit price | 15 | 19 |
| Saudi Arabia | public | 18 | 18 |
| Morocco | PPV (public price) | 5 | 10 |
| Greece | producer price (ex-factory) | 8 | 8 |
| Bahrain | retail (max) | 2 | 3 |
| United Kingdom | hospital | 3 | 3 |
61 pack listings across 51 brand entries and 6 price bases, refreshed 05 Sep 2026. Ranges span every Cefotaxime pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Cefotaxime in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
6 holders have a Canadian DIN containing Cefotaxime, across 21 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| STERIMAX INC | 3 | 2 | CEFOTAXIME SODIUM FOR INJECTION, BP | Sourceable in Canada |
| HOECHST ROUSSEL CANADA INC. | 4 | 0 | CLAFORAN ADD-VANTAGE VIALS 1GM/VIAL, CLAFORAN PWS INJ 1.0GM/VIAL, CLAFORAN PWS INJ 2.0GM/VIAL, CLAFORAN PWS INJ 500MG/VIAL | No marketed DIN |
| HOSPIRA HEALTHCARE ULC | 4 | 0 | CEFOTAXIME SODIUM FOR INJECTION, BP | No marketed DIN |
| ROUSSEL CANADA INC. | 4 | 0 | CLAFORAN 0.5GM/VIAL, CLAFORAN 1GM/VIAL, CLAFORAN 2GM/VIAL, CLAFORAN INJ 1GM/ADD-VANTAGE VIAL | No marketed DIN |
| AUROBINDO PHARMA LIMITED (UNIT VI) | 3 | 0 | CEFOTAXIME SODIUM FOR INJECTION BP | No marketed DIN |
| SANOFI-AVENTIS CANADA INC | 3 | 0 | CLAFORAN - PWS INJ 1.0G/VIAL, CLAFORAN - PWS INJ 2.0G/VIAL, CLAFORAN - PWS INJ 500MG/VIAL | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 2 G |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAMUSCULAR ; INTRAVENOUS |
| Pack configuration (monograph) | 0.5 g, 1 g, and 2 g vials. |
| Storage | Not explicitly detailed in provided text snippet beyond 'STABILITY AND STORAGE RECOMMENDATIONS' section header; typically store at 15-30°C and protect from light. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Cefotaxime |
|---|---|
| ATC code | J01DD01 |
| AHFS class | 08:12.06.12 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02352184 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2352184 |
| Brand name | CEFOTAXIME SODIUM FOR INJECTION BP |
| Generic / active ingredient | CEFOTAXIME SODIUM : 2 G |
| Market authorization holder | AUROBINDO PHARMA LIMITED (UNIT VI) |
| Health Canada schedule | Prescription |
| ATC code | J01DD01 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01DD |
| Current status | APPROVED |
| Status date | 28-May-2010 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults: 1-2g every 4-12 hours (max 12g/day) IM or IV. Neonates/Children: 50-180 mg/kg/day divided. IV bolus over 3-5 mins. Adjust dose if CrCl < 20 mL/min.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to cefotaxime sodium, cephalosporins, or the penicillin group of antibiotics. History of cephalosporin-associated hemolytic anemia.
Warnings and precautions
Anaphylaxis risk; cross-allergy with penicillins (5-10%). Severe cutaneous adverse reactions (SCAR). Rapid IV bolus may cause arrhythmia. Clostridium difficile-associated disease (CDAD).
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 21 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CEFOTAXIME SODIUM FOR INJECTION, BP | 1 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | 02434091 |
| CEFOTAXIME SODIUM FOR INJECTION, BP | 2 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | 02434105 |
| CEFOTAXIME SODIUM FOR INJECTION BP | 0.5 G | POWDER FOR SOLUTION | AUROBINDO PHARMA LIMITED (UNIT VI) | APPROVED | 02352168 |
| CEFOTAXIME SODIUM FOR INJECTION BP | 1 G | POWDER FOR SOLUTION | AUROBINDO PHARMA LIMITED (UNIT VI) | APPROVED | 02352176 |
| CEFOTAXIME SODIUM FOR INJECTION, BP | 500 MG | POWDER FOR SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | 02261502 |
| CEFOTAXIME SODIUM FOR INJECTION, BP | 250 MG | POWDER FOR SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED PRE MARKET | 02261499 |
| CEFOTAXIME SODIUM FOR INJECTION, BP | 500 MG | POWDER FOR SOLUTION | STERIMAX INC | APPROVED | 02434083 |
| CEFOTAXIME SODIUM FOR INJECTION, BP | 2.0 G | POWDER FOR SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | 02261529 |
| CEFOTAXIME SODIUM FOR INJECTION, BP | 1.0 G | POWDER FOR SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | 02261510 |
| CLAFORAN - PWS INJ 1.0G/VIAL | 1 G | POWDER FOR SOLUTION | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | 02225093 |
2 · Same class — other molecules in ATC J01DD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Ceftriaxone | CEFTRIAXONE FOR INJECTION · CEFTRIAXONE FOR INJECTION USP · CEFTRIAXONE INJECTION, USP · CEFTRIAXONE SODIUM FOR INJECTION · +7 more | 41 | 13 | Yes |
| Ceftazidime | CEFTAZIDIME FOR INJECTION BP · CEFTAZIDIME FOR INJECTION, BP · CEFTAZIDIME FOR INJECTION, USP · CEPTAZ INJ 10GM/VIAL · +13 more | 23 | 6 | Yes |
| Cefixime | AURO-CEFIXIME · SUPRAX · SUPRAX - TAB 200MG | 8 | 4 | Yes |
| Cefotaxime | CEFOTAXIME SODIUM FOR INJECTION BP · CEFOTAXIME SODIUM FOR INJECTION, BP · CLAFORAN - PWS INJ 1.0G/VIAL · CLAFORAN - PWS INJ 2.0G/VIAL · +9 more | 21 | 2 | Yes |
| Ceftizoxime | CEFIZOX | 2 | 0 | Not in Canada |
| Cefpodoxime | ORELOX | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J01D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J01DB | Cefadroxil · Cefalexin · Cefalotin · Cefazolin | 91 | 41 |
| J01DH | Doripenem · Ertapenem · Imipenem And Cilastatin · Meropenem · Meropenem And Vaborbactam | 51 | 24 |
| J01DC | Cefaclor · Cefamandole · Cefotetan · Cefoxitin · Cefprozil · +1 more | 135 | 18 |
| J01DE | Cefepime | 10 | 3 |
| J01DF | Aztreonam | 1 | 1 |
| J01DI | Ceftobiprole Medocaril · Ceftolozane And Beta-Lactamase Inhibitor | 2 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is CEFOTAXIME SODIUM FOR INJECTION BP called?
The same molecule, Cefotaxime, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| CETAXON | Latin | Morocco |
| Kefotax | Latin | Morocco, South Africa |
| CEFOTAX | Latin | Bahrain |
| CLAFORAN | Latin | Morocco |
| Oritaxim | Latin | South Africa |
| KEFOTAX IM | Latin | Morocco |
| KEFOTAX IV | Latin | Morocco |
| Klafotaxim | Latin | South Africa |
| SEFOXIME | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ask about availability of CEFOTAXIME SODIUM FOR INJECTION BP
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.